Hepatology Communications

Hepatology Communications: Official open access journal of the AASLD (@AASLDtweets)| Co-editors in Chief: @ebtapper and Dr. Wong| #SoMe Editor: @jlouissaint89

[Liver Fellow Network @LiverFellow]

🏀 Next up: Falls, Frailty, and Sarcopenia

Sirisha Gaddipati explores how physical frailty, muscle loss, and fall risk affect outcomes in cirrhosis.

Can this theme stand strong through the competition? 👇 #HepMadness2026

[AASLD @AASLDtweets]

Co-Editors @ebtapper and Carmen Chak-Lui Wong highlight October's @HepCommJournal, featuring liver decompensation, acute kidney injury in alcohol-associated hepatitis, pediatric PSC, ferroptosis, and more!

Watch below and explore the issue: https://t.co/VY23UYcVhr
https://t.co/aTTGkMdgjg

[Hepatology Communications @HepCommJournal]

📑 Seladelpar in patients with #PBC and compensated #cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies‼️
#OpenAccess #LiverX

https://t.co/Da6WPCejBy

[Hepatology Communications @HepCommJournal]

📑#MetALD is emerging as a major 🌎 liver disease phenotype‼️

⭐️10-20% of people with hepatic steatosis meet MetALD criteria❕
⚠️Metabolic dysfunction ➕ alcohol 🍻➡️ increased risks of fibrosis progression, cirrhosis, & HCC❕
#OpenAccess
https://t.co/Gyb7qcwxNp

[Scott Isaacs @scottisaacsmd]

Pleased to share our study on gaps in awareness of metabolic liver disease. Among 1,000 US adults with elevated metabolic risk, 60% recognized “fatty liver disease,” but only 13% were familiar with #MASLD and 12% with #MASH. Just 13% reported concern about liver disease. These findings reinforce why liver health needs to be part of our everyday conversations with patients about obesity and diabetes.
https://t.co/DovNHu7Bw0

[Hepatology Communications @HepCommJournal]

📑 L-Taurine for #Fatigue in Decompensated Cirrhosis⁉️

❎ Negative trial overall
⭐️ BUT, patients without anemia🩸 had a large ⬇️ in fatigue 😴, while those with anemia did not❕
#OpenAccess #LiverX

https://t.co/ajLXAvPCBh

[Hepatology Communications @HepCommJournal]

📑 Low serum pseudocholinesterase levels are associated with mortality in patients with #HCC‼️
#OpenAccess #LiverX

https://t.co/6VmTwrsQrJ

[Vinay Jahagirdar @vinayjaha]

Have you signed up for #HepMadness2026 yet? 🏆

16 hepatology themes go head-to-head!

A great learning opportunity with recent articles handpicked from @LTxJournal & @HepCommJournal, summarized by team @LiverFellow.

Open to ALL! Make your picks by Oct 31! 🔥

Sign up & FAQs here 🔗 https://t.co/JsKCZmPUFm…

🥇 to be announced at #TLM2026

@AASLDtweets @AASLDFoundation @AASLDPresident @ebtapper @jlouissaint89 @WAleyadeh @SarahKhan9894

[Elliot Tapper @ebtapper]

Huge review on patient and caregiver reported outcome in ascites from Dr Sumita Verma’s group https://t.co/GyRU67kt33

Open access in @HepCommJournal

Everything from pooled estimates to impact of interventions

[Liver Fellow Network @LiverFellow]

5/5 Does this theme make your next round—or go all the way? 🏆

Submit your bracket by Oct 31:
https://t.co/gXZ4RJPgZZ

@LTxJournal @HepCommJournal @aasldtweets #HepMadness2026

[Liver Fellow Network @LiverFellow]

5/5 Is this your championship pick? 🏆

Explore the evidence and submit your bracket by Oct 31:
https://t.co/gXZ4RJPgZZ

@LTxJournal @HepCommJournal @aasldtweets #HepMadness2026

[Hepatology Communications @HepCommJournal]

📑 Group-based #telehealth 💻behavioral interventions for chronic liver disease‼️

A 14-week group telehealth intervention achieved 84% retention & 91% session attendance❕
⭐️Improvement trends in stress, coping, relaxation 🧘, & sleep hygiene 😴

https://t.co/X8yZKnN8YN

[Liver Fellow Network @LiverFellow]

1/6 🚨 THE BRACKET IS LIVE 🚨

HepMadness 2026 starts NOW.

16 themes. 4 rounds. 1 champion 🏆

The best hepatology and transplant science of the year, going head to head. Who survives?

#HepMadness2026

https://t.co/oY56f50r1m

[Hepatology Communications @HepCommJournal]

📑 Autoimmune liver diseases in Latin America 🌎: Current landscape and challenges‼️
#OpenAccess #LiverX #PBC #AIH

https://t.co/Kb9ZPMBQff

[Hepatology Communications @HepCommJournal]

📑 Molnupiravir is effective against hepatitis E virus infection in an animal model‼️🦠
#OpenAccess #LiverX

https://t.co/sSHfvT9uSc

[AASLD @AASLDtweets]

🎉 A historic milestone for AASLD journals!

@HEP_Journal has achieved its highest-ever #ImpactFactor of 21.3, reinforcing its position as a global leader in liver research and scientific discovery.

The milestones don't stop there! @HepCommJournal also reached a record-high Impact Factor of 6.2.

These achievements reflect the exceptional contributions of our authors, reviewers, and editorial teams and AASLD's continued commitment to advancing liver science and improving patient care worldwide.

Read the full announcement: https://t.co/G1xB0LnzgI

[Hepatology Communications @HepCommJournal]

📑 Integrating behavioral health into hepatology improves #AUD care‼️🍺

⬆️ Any AUD treatment: 80% vs 28%
⬆️ Psychotherapy: 76% vs 24%
⬆️ Pharmacotherapy: 41% vs 12% 💊
#OpenAccess #LiverX
@ponnivp
https://t.co/gNzT0fpE05

[AASLD @AASLDtweets]

🔥 HOT TOPIC

📘 @HepCommJournal

Nearly 1 in 5 youth with biopsy-confirmed #MASLD began drinking during adolescence or early adulthood.

In the largest longitudinal study of its kind, researchers followed more than 1,100 youth and found that alcohol use was associated with faster increases in liver enzymes, reinforcing the importance of routine alcohol screening and developmentally tailored counseling in pediatric MASLD care.

Read the article: https://t.co/HxtlGyPEpZ

[Hepatology Communications @HepCommJournal]

📑 Better pathways ➡️ better detection 🔎of advanced #MASLD‼️

⭐️A 2-step FIB4/MAF4/NFS ➡️ VCTE pathway ⬆️ correct hepatology referral rates❕
#OpenAccess #LiverX

https://t.co/Yo8JfnVduZ

[Hepatology Communications @HepCommJournal]

📑 "Lean" doesn't mean mild #MASLD‼️

💉 Histologic severity was identical in normal-weight and overweight adults:
⭐️ 26% had advanced fibrosis
⭐️ 8% had #cirrhosis
Severity ⬆️ once BMI > 30
#OpenAccess #LiverX

https://t.co/erhGCKksjC